Persons from racial and ethnic minority groups receiving medication for opioid use disorder experienced increased difficulty accessing harm reduction services during COVID-19

Robert Rosales*, Tim Janssen, Julia Yermash, Kimberly R. Yap, Elizabeth L. Ball, Bryan Hartzler, Bryan R. Garner, Sara J. Becker

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

Introduction: The COVID-19 pandemic collided with the opioid epidemic and longstanding health inequities to exacerbate the disproportionate harms experienced by persons with opioid use disorder (OUD) who self-identify as from racial and ethnic minority groups. Disrupted access to harm reduction services (e.g., naloxone, sterile syringes, recovery support) is one pathway whereby COVID-19 might exacerbate health disparities. We tested the hypothesis that persons receiving medication for opioid use disorder (MOUD) who self-identify as from racial/ethnic minority groups would experience more disruptions in access to harm reduction services than persons identifying as non-Hispanic White, even when controlling for severity of opioid use and sociodemographics (e.g., education, income, biological sex, age). Methods: Analyses used data from a cluster randomized trial that had enrolled 188 patients, all of whom had provided baseline data on sociodemographics and severity of opioid use, across eight opioid treatment programs. Data collectors re-contacted participants between May and June 2020 and 133 (71% response rate) agreed to complete a survey about access to harm reduction services. Results: Twenty-six respondents (20%) identified as from racial/ethnic minority groups (predominantly Black, Hispanic, and/or biracial). Between 7% and 27% of respondents reported disrupted access to harm reduction services. Logistic regressions indicated that persons identifying as from racial/ethnic minority groups were 8–10 times more likely than persons identifying as non-Hispanic White to report reduced access to naloxone and sterile syringes (p < .01), even when accounting for potential confounding variables. Conclusions: This report concludes with a discussion of potential outreach strategies and policies to advance more equitable access to essential harm reduction services.

Original languageEnglish (US)
Article number108648
JournalJournal of Substance Abuse Treatment
Volume132
DOIs
StatePublished - Jan 2022

Funding

Funding for this study was provided by National Institute on Drug Abuse (NIDA) Grant R01DA046941 , awarded to Multiple Principal Investigators Becker and Garner, and the dual-funded National Institute on Minority Health and Health Disparities (NIMHD) and National Institutes of Health (NIH) Office of the Director Grant K08MD015289 , awarded to Principal Investigator Rosales. NIDA, NIMHD, and the NIH Office of the Director had no role in the study design, collection, analysis or interpretation of the data, writing the manuscript, or the decision to submit the paper for publication.

Keywords

  • COVID-19
  • Disparities
  • Harm reduction
  • Inequity
  • Opioids

ASJC Scopus subject areas

  • Phychiatric Mental Health
  • Medicine (miscellaneous)
  • Clinical Psychology
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'Persons from racial and ethnic minority groups receiving medication for opioid use disorder experienced increased difficulty accessing harm reduction services during COVID-19'. Together they form a unique fingerprint.

Cite this